healthcare reimbursement
How much governments and insurers pay for care, tests and drugs, and whether they cover them at all.
Exposure · 25 companies
ADRX ADARx Pharmaceuticals, Inc.
Exposed“Payers can limit coverage, impose cost-sharing or favor cheaper alternatives.”
APMD Apnimed, Inc.
Exposed“Our ability to successfully commercialize Oxnimbi or any future product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government healthcare programs (e.g., Medicare, Medicaid), managed care providers, private health insurers, health maintenance organizations, and other organizations.”
ASPE Aspen Neuroscience, Inc.
Exposed“Successful sales of our products in the U.S. market, if approved, will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs or private health insurance (including managed care plans).”
BRVE Braveheart Bio, Inc.
Exposed“Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.”
CAPR CAPRICOR THERAPEUTICS, INC.
Exposed“Infusion logistics, treatment-center capacity, site-of-care requirements, safety and labeling, competition, reimbursement and physician and patient adoption could limit uptake even if the product is approved.”
- Revenue$0vs $0 year ago
- Net income−$42.7MYoY −73.6%
CDNA CareDx, Inc
Exposed“More broadly, coverage changes, audits, payer denials, inadequate private-payer rates and negative technology assessments could reduce reimbursement or utilization.”
- Revenue$379.8MYoY +13.8%
- Net income−$21.4Mvs $52.5M year ago
- Revenue$139.4MYoY +39.3%
- Net income$19.3Mvs $1.7M year ago
CVS CVS Health
Exposed“Pharmacy & Consumer Wellness: Q3 revenue and operating income reflected regulatory-related drug price reductions, generic introductions and reimbursement pressure, partly offset by favorable drug mix, brand inflation, prescription volume and Rite Aid contributions.”
- Revenue$108.4BYoY +5.4%
- Net income$2.2Bvs −$4.0B year ago
DHR Danaher Corporation
Exposed“China’s 9M weakness partly reflected healthcare pricing and reimbursement changes, although sales there returned to year-over-year growth in Q3.”
- Revenue$6.6BYoY +8.3%
- Net income$1.2BYoY +36.0%
ELV Elevance Health
Exposed“Rate-setting lags and delayed premium approvals may leave government-program rates inadequate or delay revenue recognition.”
- Revenue$51.4BYoY +1.4%
- Net income$1.4BYoY +14.8%
EMI Encore Medical, Inc.
Exposed“Adoption also depends on third-party reimbursement; coverage restrictions, reimbursement cuts, hospital purchasing practices, group purchasing negotiations, and competitor discounts may constrain demand and margins.”
HCA HCA Healthcare
Exposed“Federal Budget Act and CMS restrictions on provider taxes and Medicaid supplemental or state-directed payments could reduce federal matching funds, pressure state budgets, and affect reimbursement or coverage; the timing and impact remain uncertain.”
- Revenue$19.8BYoY +3.6%
- Net income$1.6BYoY −3.9%
ISRG Intuitive Surgical
Exposed“Because there is often no separate payment for the use of our products, the additional cost associated with the use of our products can affect the profit margin of the hospital or surgery center where the procedure is performed.”
- Revenue$10.1BYoY +20.5%
- Net income$2.9BYoY +23.0%
- Revenue$3.0BYoY +21.7%
- Net income$522.8MYoY −25.8%
LTGO Latigo Biotherapeutics, Inc.
Exposed“Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for our drug candidates, if approved, will be available from government health administration authorities, private health insurers and other organizations.”
MYGN Myriad Genetics
Exposed“Presently, approximately 61% of our revenue comes from private third-party payors.”
- Revenue$824.5MYoY −1.6%
- Net income−$365.9MYoY −187.4%
- Revenue$202.7MYoY −1.5%
- Net income−$43.9MYoY −60.2%
NUOX NuvOx Therapeutics, Inc.
Exposed“Pricing, reimbursement, formulary access, comparative efficacy, safety and convenience will affect demand.”
RGNA Regenlab USA Inc.
Exposed“Reimbursement is uncertain and pricing pressure may constrain demand, including through public-hospital bids.”
RZRA Rezera Inc.
Exposed“Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval.”
STA Starton Holdings, Inc.
Exposed“The potential market for STAR-LLD may be smaller than estimated, and adoption depends on meaningful advantages over existing treatments, physician and patient acceptance, and adequate coverage and reimbursement.”
UNH UnitedHealth Group
Exposed“Medicare Advantage faces funding pressure: multiyear rate shortfalls remain below forward medical cost trends despite the 2027 Final Notice moving toward those trends, and risk-adjustment changes further reduce funding, particularly for members with significant health and social needs.”
- Revenue$112.7BYoY −0.4%
- Net income$4.1BYoY +75.0%
VOGX Vogenx, Inc.
Exposed“Even approval may not yield meaningful sales: physician and patient adoption, coverage, reimbursement, pricing, and cost-effective supply are uncertain.”
VRTX Vertex Pharmaceuticals
Exposed“The company also must advance and commercialize products, including povetacicept for IgAN, and secure adequate payer coverage, pricing, and reimbursement.”
- Revenue$3.4BYoY +11.8%
- Net income$653.6MYoY −39.6%
WELL Welltower
Exposed“Other significant uncertainties include changes in healthcare regulation and reimbursement, government investigations, and operators’ ability to obtain affordable liability insurance;”
- Revenue$3.7BYoY +38.4%
- Net income$396.6MYoY +41.4%
WMT Walmart
Exposed“Pharmacy and health-and-wellness results are exposed to reimbursement rates, payer mix, formularies, drug costs, generic substitution, PBM consolidation, online competition and government drug-pricing initiatives.”
- Revenue$713.2BYoY +4.7%
- Net income$21.9BYoY +12.6%
- Revenue$187.9BYoY +5.9%
- Net income$6.4BYoY −9.4%
No companies have a recent 8-K matching these events.
No companies in the selected roles.